NEW YORK, Dec. 16, 2025 /PRNewswire/ — This week, Sushi announced a major strategic development in the protocol’s long-term roadmap, backed by a significant investmentNEW YORK, Dec. 16, 2025 /PRNewswire/ — This week, Sushi announced a major strategic development in the protocol’s long-term roadmap, backed by a significant investment

Sushi Announces Strategic Investment and New Leadership to Accelerate Next Phase of Growth

NEW YORK, Dec. 16, 2025 /PRNewswire/ — This week, Sushi announced a major strategic development in the protocol’s long-term roadmap, backed by a significant investment from Synthesis, led by entrepreneur Alex McCurry. As part of this investment, Synthesis has acquired more than 10 million $SUSHI tokens, underscoring its conviction in Sushi’s future and its role in the evolving DeFi landscape.

Alex McCurry will join the Sushi Protocol as its new chief executive. A Forbes 30 Under 30 honoree and seasoned founder, Alex has built and scaled eight-figure software companies and brings deep operational, product, and DeFi expertise to Sushi’s next chapter.

The announcement follows a pivotal year for Sushi: in 2024, the protocol became profitable, generating over $10 million in revenue across its Automated Market Maker (AMM), aggregator, and related product lines. With Synthesis’s backing, Sushi aims to scale this annual revenue in the coming years through disciplined growth, clear execution, and sustainable business fundamentals.

Sushi’s ecosystem continues to expand through key partnerships, including the rapid growth of Katana, a Layer 2 (L2) network supported by Polygon. Katana has accumulated over $100 million in TVL on Sushi, strengthening Sushi’s position as a foundational liquidity and routing layer for established and emerging networks.

As part of this transition, Sushi Labs managing director Jared Grey will step down from his leadership role and transition into an advisory position, continuing to support Sushi with long-term strategic guidance.

Under Alex’s leadership, Sushi will focus on four core priorities:

  • Deepening liquidity and execution quality across the protocol
  • Expanding protocol-owned liquidity (POL) and sustainable revenue streams
  • Strengthening tokenomics and aligning long-term incentives across the ecosystem
  • Supporting partners and builders who choose Sushi as their liquidity home

This leadership transition and strategic investment mark the beginning of a renewed phase of growth for Sushi, with an emphasis on operational excellence, ecosystem expansion, and user-aligned value creation.

About Sushi

SushiSwap is a leading decentralized exchange (DEX) and Aggregator that lets you SWAP ANYTHING. Powered by an advanced aggregation stack, SushiSwap ensures optimal pricing for swaps and seamless user experiences across dozens of networks.

Sushi Labs, the development arm of Sushi DAO, is building a multi-DEX powerhouse with strategic partnerships and cutting-edge DeFi primitives. For more information, visit SushiSwap.

Press Contact
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sushi-announces-strategic-investment-and-new-leadership-to-accelerate-next-phase-of-growth-302644077.html

SOURCE SushiSwap

Market Opportunity
SUSHI Logo
SUSHI Price(SUSHI)
$0.3079
$0.3079$0.3079
+2.32%
USD
SUSHI (SUSHI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26